Keros Therapeutics (KROS) Receivables - Net (2021 - 2025)

Keros Therapeutics has reported Receivables - Net for 4 years, with the latest figure at $3.6 million in Q4 2025.

• For the quarter ending Q4 2025, Receivables - Net rose 30.09% year-over-year to $3.6 million; the trailing twelve-month figure through Dec 2025 stood at $3.6 million (up 30.09% YoY), and the FY2025 full-year result was $3.6 million, up 30.09% from the prior year.
• Receivables - Net for Q4 2025 stood at $3.6 million, up from $3.5 million in the prior quarter.
• The five-year high for Receivables - Net was $18.0 million in Q4 2021, with the low at $4000.0 in Q2 2024.
• Historically, Receivables - Net has averaged $5.6 million across 4 years, with a median of $2.7 million in 2024.
• The largest YoY upside for Receivables - Net was 395300.0% in 2025 against a maximum downside of 30.09% in 2025.
• Keros Therapeutics' Receivables - Net stood at $18.0 million in 2021, then slumped by 99.21% to $143000.0 in 2023, then jumped by 1817.48% to $2.7 million in 2024, then soared by 30.09% to $3.6 million in 2025.
• The last three Receivables - Net figures came in at $3.6 million (Q4 2025), $3.5 million (Q3 2025), and $15.8 million (Q2 2025), per Business Quant data.